13F filer · CIK 2106181
Kalehua Capital Management LLC
DALLAS, TX · filing since Q4 2025 · last filing Aug 19, 2026
Reported value
$313.5M
+$53.5M vs prior
Positions
26
New / sold out
8 / 7
Added / reduced
5 / 3
Turnover
22.7%
buys $65.2M · sells $67.9M
Top-10 weight
70.1%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Karyopharm Therapeutics Inc | +1,371,288 | – | +$13.4M |
| New | Inflarx Nv | +5,795,538 | – | +$13.0M |
| New | Cyclerion Therapeutics Inc | +3,302,700 | – | +$11.2M |
| Added | Veradermics Inc | +42,816 | +17.2% | +$5.3M |
| Added | Korro Bio Inc | +295,664 | +270.3% | +$3.9M |
| New | Nuvectis Pharma Inc | +200,000 | – | +$3.7M |
| New | Milestone Pharmaceuticals Inc | +2,538,474 | – | +$3.4M |
| Added | Aclaris Therapeutics Inc | +494,809 | +15.6% | +$2.6M |
| New | Adlai Nortye | +226,415 | – | +$2.6M |
| Added | Inhibikase Therapeutics Inc | +1,149,282 | +17.7% | +$2.3M |
3 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Relay Therapeutics Inc | -1,802,914 | -100.0% | $-17.9M |
| Reduced | Uniqure Nv | -343,997 | -68.4% | $-15.8M |
| Reduced | EA SERIES TRUST | -110,512 | -32.8% | $-12.9M |
| Sold out | Oruka Therapeutics Inc | -237,048 | -100.0% | $-11.6M |
| Sold out | PepGen Inc | -1,729,961 | -100.0% | $-3.1M |
| Sold out | Tenaya Therapeutics Inc | -4,000,000 | -100.0% | $-2.8M |
| Sold out | Kalaris Therapeutics Inc | -271,170 | -100.0% | $-1.6M |
| Reduced | Instil Bio Inc | -123,679 | -38.3% | $-951.1K |
| Sold out | DiaMedica Therapeutics Inc | -124,976 | -100.0% | $-846.1K |
| Sold out | LONGEVERON INC | -347,539 | -100.0% | $-361.4K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Veradermics IncCOMMON STOCK | 291,390 | $35.8M | 11.43% |
| 2 | X4 Pharmaceuticals IncCOM NEW | 7,445,680 | $34.8M | 11.09% |
| 3 | EA SERIES TRUSTALPHA ARCH 1-3 | 226,188 | $26.5M | 8.45% |
| 4 | Compass Pathways PlcSPONSORED ADS | 1,639,384 | $23.2M | 7.40% |
| 5 | Surrozen IncCOM NEW | 770,356 | $20.0M | 6.38% |
| 6 | Aclaris Therapeutics IncCOM | 3,664,730 | $19.4M | 6.18% |
| 7 | Sionna Therapeutics IncCOM | 394,144 | $17.3M | 5.53% |
| 8 | Inhibikase Therapeutics IncCOM NEW | 7,643,780 | $15.5M | 4.95% |
| 9 | Pharvaris NVCOM | 397,544 | $13.7M | 4.39% |
| 10 | Karyopharm Therapeutics IncCOM NEW | 1,371,288 | $13.4M | 4.27% |
16 more rows. Subscribe for $29/month to see every row, download the data and use the API.